Hereditary orotic aciduria is a rare inherited genetic disorder that affects pyrimidine nucleotide synthesis in the body. It is caused by a mutation in the UMPS gene that encodes for the enzyme orotate phosphoribosyltransferase (OPRT). This enzyme plays a vital role in the pyrimidine salvage pathway involved in the biosynthesis of uridine monophosphate (UMP), which is required for the formation of DNA and RNA. A deficiency of OPRT due to a mutation results in orotic acid accumulation in the blood and urine.

Symptoms of Uridine Monophosphate Synthase Deficiency

The symptoms of uridine monophosphate synthase deficiency usually present early in life and vary from mild to severe. Common symptoms include developmental delay, intellectual disability, seizures, microcephaly, and feeding difficulties in infants and children. Some patients may experience recurrent infections, vomiting, diarrhea, and failure to thrive. Facial dysmorphism with midface hypoplasia and epicanthal folds is also observed in many affected individuals. Symptom severity often correlates with the degree of enzymatic deficiency, however, significant variability exists even among individuals with the same mutation. Early diagnosis and treatment are crucial to prevent neurological complications.

Genetics and Inheritance Pattern

Hereditary Orotic Aciduria is inherited in an autosomal recessive manner. This means an individual must inherit two copies of the mutated UMPS gene - one from each parent - to be affected by the disorder. carriers who have only one copy of the mutated gene are usually unaffected but can pass the gene to their offspring. The estimated gene frequency of UMPS mutations varies in different populations worldwide. Consanguinity is frequently reported in families with multiple affected individuals, indicating parental relatedness increased the risk of offspring inheriting two recessive alleles. Prenatal diagnosis through molecular or enzymatic testing is possible for families with a previously identified mutation.

Pathophysiology and Biochemical Basis

The UMPS gene provides instructions for making the enzyme orotate phosphoribosyltransferase (OPRT), which plays a key role in the pyrimidine salvage pathway. This pathway helps recycle pyrimidine bases from nucleic acid degradation and provides an alternative to de novo pyrimidine biosynthesis. OPRT specifically catalyzes the conversion of orotic acid to orotidylic acid monophosphate in the presence of phosphoribosyl pyrophosphate (PRPP).

In uridine monophosphate synthase deficiency, mutations in UMPS disrupt OPRT enzyme function to varying degrees, depending on the type and location of the mutation. Even residual enzymatic activity below 10% of normal can cause disease. The deficiency prevents orotic acid from being incorporated into the pyrimidine nucleotide pool, leading to its accumulation in the blood and urine. This disrupts DNA/RNA synthesis and cell metabolism, particularly in rapidly dividing cells like those in the brain and other tissues. If left untreated, chronic pyrimidine pool imbalance causes progressive damage over time.

Diagnosis

The diagnosis of hereditary orotic aciduria is made through biochemical and molecular genetic testing. Initial screening involves a urine orotic acid test, which will be markedly elevated in affected individuals. Plasma amino acid analysis may also reveal elevated orotic acid levels. Definitive diagnosis requires demonstration of deficient OPRT enzyme activity in fibroblasts or lymphocytes and identification of biallelic pathogenic variants in the UMPS gene through DNA-based testing. Prenatal diagnosis is possible through similar analyses of maternal blood cells or amniocytes obtained through amniocentesis.

Differential diagnoses to consider include other causes of secondary, non-genetic orotic aciduria such as liver disease or certain drug effects interfering with pyrimidine metabolism. Careful evaluation of clinical manifestations, family history, and appropriate biochemical/genetic testing can distinguish uridine monophosphate synthase deficiency from other conditions. Prenatal diagnosis has also benefited families with a known family history seeking early information on an at-risk pregnancy.

Treatment and Management

Currently, the only effective treatment for uridine monophosphate synthase deficiency is pyrimidine supplementation with uridine monophosphate (UMP) or orotic acid. This bypasses the blocked step in the salvage pathway and provides substrates for DNA/RNA biosynthesis. UMP is administered orally and absorbs efficiently from the gastrointestinal tract. Treatment should begin in early infancy to prevent neurological consequences and is typically lifelong. Close monitoring is needed to adjust dosage based on clinical response and monitor for side effects like diarrhea.

Other supportive measures include treating infections promptly, ensuring adequate nutrition and calorie intake to support growth and development. Seizures are managed with anti-epileptic medications. Physical, occupational and speech therapies may help address related neurodevelopmental issues. Liver transplantation has also been explored but long-term benefits are unclear due to incomplete enzyme correction in all tissues. Gene therapy approaches hold promise but remain investigational. Prognosis depends on how quickly treatment.

Get more insights on Hereditary Orotic Aciduria